Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $161K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $161K.

Context

  • Cost of revenue amounted to 55.1% of revenue in FY2025, up 55.1 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $161K or moves back toward the trailing-twelve-month quarterly average of $40.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$161K— QoQ
Last fiscal yearDec 2025
$900K— YoY
LTMMar 2026
$161K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
900K USD
Year-over-year change
—

Cost of Revenue vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Cost of revenue amounts to 5.1% of revenue for RANI, versus a peer median of 5.3%.
RANI Competitors
Cost of Revenue for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRDFCardiff Oncology, Inc.LTM Mar 2026$11.58M USD+18.8%—2205.7%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$8.32M USD+18.0%—47.4%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF-92.3%-62.9%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$289K USD-75.2%+2.2%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$161K USD——5.1%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$149K USD-99.1%——
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$95K USD——5.3%
IPHAInnate Pharma S.A.FY2025€0 EUR-100.0%—0.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$0 USD—-14.4%0.0%
Peer median (excluding RANI) —-83.8%-14.4%5.3%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.72M001.03M1.63M
Cost of Revenue00822K0900K
Gross Profit2.72M0(822K)1.03M733K
Gross Margin100.0%——100.0%44.9%
Research & Development26.48M36.61M39.62M26.68M20.21M
Selling, General & Admin27.83M26.84M26.48M23.95M19.74M
Operating Expenses54.32M63.45M65.28M54.34M39.04M
Depreciation & Amortization497K548K822K1.03M900K
EBITDA(52.08M)(61.66M)(61.98M)(50.52M)(37.16M)
EBITDA Margin-1917.0%——-4914.7%-2275.5%
Operating Income(51.6M)(63.45M)(66.1M)(53.31M)(38.31M)
Operating Margin-1899.1%——-5186.2%-2346.0%
Interest Income89K1.25M3.3M1.76M827K
Interest Expense466K1.07M5.09M5.03M2.89M
Other Income / Expenses(1.45M)177K(1.78M)23.3M(2.64M)
Income Before Tax(53.05M)(63.27M)(67.88M)(30.02M)(40.95M)
Pre-Tax Margin-1952.4%——-2920.0%-2507.7%
Income Tax Expense41K70K026.57M0
Net Income(8.33M)(30.59M)(33.97M)(30.02M)(29.67M)
Net Margin-306.6%——-2920.0%-1817.1%
EPS (Basic)(0.42)(1.28)(1.33)(1.05)(0.45)
EPS (Diluted)(0.42)(1.28)(1.33)(1.05)(0.45)
Weighted Avg Shares19.53M23.82M25.51M28.48M66.14M
Weighted Avg Shares (Diluted)19.53M23.82M25.51M28.48M66.14M

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.